[1]中国医师协会介入医师分会介入围手术专委会 、中国医师协会介入医师分会介入临床诊疗指南专委会.肝脏恶性肿瘤介入治疗围术期疼痛管理专家共识(2022)[J].介入放射学杂志,2022,31(10):943-948.
 Interventional Perioperative Committee,Interventional Physician Branch of Chinese Medical Doctor Association,Interventional Clinical Diagnosis and Treatment Guidelines Committee,et al.Expert consensus on the interventional perioperative pain management for patients with liver malignancy(2022 Edition)[J].journal interventional radiology,2022,31(10):943-948.
点击复制

肝脏恶性肿瘤介入治疗围术期疼痛管理专家共识(2022)()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
31
期数:
2022年10
页码:
943-948
栏目:
指南与共识
出版日期:
2022-11-07

文章信息/Info

Title:
Expert consensus on the interventional perioperative pain management for patients with liver malignancy(2022 Edition)
作者:
中国医师协会介入医师分会介入围手术专委会 、中国医师协会介入医师分会介入临床诊疗指南专委会
Author(s):
Interventional Perioperative Committee Interventional Physician Branch of Chinese Medical Doctor Association; Interventional Clinical Diagnosis and Treatment Guidelines Committee Interventional Physician Branch of Chinese Medical Doctor Association
关键词:
【关键词】 肝脏 恶性肿瘤 介入治疗 围术期 疼痛 专家共识
文献标志码:
A
摘要:
【摘要】 疼痛是肝脏恶性肿瘤介入治疗围术期较常见的不良反应,为促进肝脏恶性肿瘤介入治疗围术期疼痛管理规范化,减轻患者痛苦,提高患者舒适度,中国医师协会介入医师分会介入围手术专委会和介入临床诊疗指南专委会组织撰写本共识,撰写成员由医疗、护理、麻醉和药学专家组成。本共识系统总结了国内外相关文献,以现有证据为基础,结合我国临床实践,从介入治疗围术期疼痛的影响因素与机制、疼痛评估、药物镇痛、疼痛护理、镇痛药物常见不良反应的预防与护理方面提供指导与推荐。

参考文献/References:

[1] Cao B, Bray F, Ilbawi A, et al. Effect on longevity of one- third reduction in premature mortality from non- communicable diseases by 2030: a global analysis of the Sustainable Development Goal health target[J]. Lancet Glob Health, 2018, 6: e1288- e1296.
[2] Zhou B, Wang J, Yan Z, et al. Liver cancer: effects, safety, and cost- effectiveness of controlled- release oxycodone for pain control after TACE[J]. Radiology, 2012, 262: 1014- 1021.
[3] 罗 君,邵国良,郑家平,等. 原发性肝癌肝动脉化疗栓塞术后腹痛的发生规律及影响因素[J]. 介入放射学杂志, 2017, 26:613- 617.
[4] 冷希圣,韦军民,刘连新,等. 普通外科围手术期疼痛处理专家共识[J]. 中华普通外科杂志, 2015, 30:166- 173.
[5] 周 石,安天志,程永德. 无痛- 介入手术新方向[J]. 介入放射学杂志, 2015, 24:747- 749.
[6] 中国抗癌协会癌症康复与姑息治疗专业委员会难治性癌痛学组. 难治性癌痛专家共识(2017年版)[J]. 临床医学研究与实践, 2017, 44:201.
[7] Benzakoun J, Ronot M, Lagadec M, et al. Risks factors for severe pain after selective liver transarterial chemoembolization[J]. Liver Int, 2017, 37: 583- 591.
[8] 孟永斌,陈红云,翟笑枫,等. 原发性肝癌患者肝动脉化疗栓塞术后疼痛的影响因素分析[J]. 肿瘤学杂志, 2013, 19:722- 725.
[9] 沈海洋,杨 光,刘瑞宝,等. 原发性肝癌患者肝动脉化疗栓塞术后肝区疼痛的临床意义[J]. 介入放射学杂志, 2010, 19:297- 300.
[10] 蔡平凡,田文静,王 莹,等. 肝癌经动脉化疗栓塞术后急性腹痛预测模型构建[J]. 现代消化及介入诊疗, 2021, 26:1400- 1403.
[11] 徐 城,杨晓秋,刘丹彦. 常用的疼痛评估方法在临床疼痛评估中的作用[J]. 中国疼痛医学杂志, 2015, 21:210- 212.
[12] No authors listed.World Health Organization: WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents 2018[EB/OL]. https://www.who.int/publications/i/item/9789241550390, 2019- 01- 01.
[13] 中华人民共和国国家卫生健康委员会.癌症疼痛诊疗规范(2018年版)[J]. 临床肿瘤学杂志, 2018, 23:937- 944.
[14] 覃旺军,任夏洋,李 然,等. 癌症疼痛管理药学专家共识[J].中国疼痛医学杂志, 2019, 25:801- 807.
[15] 中国抗癌协会肿瘤麻醉与镇痛专业委员会.中国肿瘤患者围术期疼痛管理专家共识(2020版)[J]. 中国肿瘤临床, 2020, 47:703- 710.
[16] Bandieri E, Romero M, Ripamonti C, et al. Randomized trial of low- dose morphine versus weak opioids in moderate cancer pain[J]. J Clin Oncol, 2016, 34: 436- 442.
[17] Maltoni M, Scarpi E, Modonesi C, et al. A validation study of the WHO analgesic ladder: a two- step vs three- step strategy[J]. Supportive Care in Cancer, 2005, 13: 888- 894.
[18] Marinangeli F, Ciccozzi A, Leonardis M, et al. Use of strong opioids in advanced cancer pain: a randomized trial[J]. J Pain Symptom Manage, 2004, 27: 409- 416.
[19] Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines[J]. Ann Oncol, 2018, 29(Suppl 4): iv166- iv191.
[20] Mcnicol ED, Ferguson MC, Hudcova J. Patient controlled opioid analgesia versus non- patient controlled opioid analgesia for postoperative pain[J]. Cochrane Database Syst Rev, 2015: CD003348.
[21] 林雪棉,郑淑华. 疼痛强化管理在原发性肝癌患者肝动脉化疗栓塞术后肝区疼痛中的应用效果观察[J]. 护理实践与研究,2017, 14:91- 93.
[22] Wang ZX, Liu SL, Sun CH, et al. Psychological intervention reduces postembolization pain during hepatic arterial chemoembo-lization therapy: a complementary approach to drug analgesia[J]. World J Gastroenterol, 2008, 14: 931- 935.
[23] 肖书萍,肖 芳,郑传胜,等. 全周期分阶段护理在载药微球治疗肝癌患者中的应用[J]. 介入放射学杂志, 2020, 29:1262- 1267.
[24] 李 媛. 多模式镇痛护理对肝癌介入治疗患者疼痛程度及焦虑症状的影响[J]. 临床护理杂志, 2019, 18:41- 44.
[25] 肖书萍,李 玲,周国锋. 介入治疗与护理[M]. 北京:中国协和医科大学出版社, 2010.
[26] World Health Organization. Cancer pain relief(1986)[EB/OL] https://apps.who.int/iris/handle/10665/43944,1986- 01- 01.
[27] 范婷婷,张先翠,姜翠凤. MEWS联合NRS评分在急诊分级分诊中的应用[J]. 皖南医学院学报, 2019, 38:399- 402.
[28] Blackburn H, West S. Management of postembolization syndrome following hepatic transarterial chemoembolization for primary or metastatic liver cancer[J]. Cancer Nurs, 2016, 39: E1- E18.
[29] 方 金. 阿片类药物相关性便秘的护理干预研究进展[J]. 中国临床护理, 2021, 13:63- 65.
[30] Romagnoli S, Fanelli F, Barbani F, et al. CIRSE standards of practice on analgesia and sedation for interventional radiology in adults[J]. Cardiovasc Intervent Radiol, 2020, 43: 1251- 1260.
[31] Quinlan- Colwell A, Rae D, Drew D. Prescribing and administering opioid doses based solely on pain intensity: update of aposition statement by the American society for pain management nursing[J]. Pain Manag Nurs, 2022, 23: 68- 75.

相似文献/References:

[1]何乾文,何远忠,罗来华,等.自制简易碘油推送器[J].介入放射学杂志,2000,(03):134.
[2]昝露霞,刘树惠,程永德,等.介入病房护理工作的体会[J].介入放射学杂志,1997,(01):51.
[3]吉美玲.肾癌介入治疗及护理[J].介入放射学杂志,1997,(04):236.
[4]余建军.直肠癌手术前介入治疗三例[J].介入放射学杂志,1998,(02):102.
[5]韩旭,杨家政,左庆云,等.选择性肝动脉灌注化疗及栓塞治疗原发性巨块型肝癌[J].介入放射学杂志,1998,(03):171.
[6]黄小明,于淼,暴军玲,等.甲氧氯普胺治疗肝癌介入治疗中的胃肠道反应[J].介入放射学杂志,1998,(04):245.
[7]邓力,陈庆强,卢秋红.华蟾素配合介入治疗原发性肝癌临床观察[J].介入放射学杂志,1999,(01):43.
[8]詹迎江,虞喜豪,张正国,等.保尔佳与介入治疗恶性肿瘤联合应用的初步体会[J].介入放射学杂志,1994,(02):109.
[9]萧湘生.肺癌介入治疗若干问题探讨[J].介入放射学杂志,1994,(03):125.
[10]许秀芳,程永德,丁美娟,等.肺癌介入治疗后的护理[J].介入放射学杂志,1994,(04):232.

备注/Memo

备注/Memo:
(收稿日期:2022- 06- 20)
(本文编辑:新 宇)

更新日期/Last Update: 2022-11-02